Risk Factors of Venous Thrombotic Event in Interstitial Lung Disease

September 20, 2026 updated by: Basant Mahmoud Ahmed, Sohag University

Incidence , Risk Factors and Clinical Outcomes of Venous Thrombotic Events in Hospitalized Patients With Interstitial Lung Disease

This study aims to determine the incidence of venous thromboembolic events (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), among hospitalized patients with interstitial lung disease (ILD). It will also identify potential risk factors associated with VTE and evaluate its impact on clinical outcomes. Patients with ILD admitted to the hospital will be assessed for clinical characteristics, disease severity, risk factors for thrombosis, and the occurrence of DVT or PE during hospitalization. The study findings may help improve early recognition of VTE and guide appropriate preventive and diagnostic strategies in hospitalized patients with ILD.

Study Overview

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

"The study will include adult patients aged 18 years or older who are admitted to the Department of Chest Diseases, Sohag University Hospital, with a confirmed diagnosis of interstitial lung disease (ILD). Eligible patients will be assessed for risk factors, clinical characteristics, and occurrence of venous thrombotic events during hospitalization.

Description

Inclusion Criteria:

  • Age ≥ 18 years. Patients admitted to the respiratory ICU, Chest Department

Exclusion Criteria:

  • Age < 18 years. Patients already receiving therapeutic anticoagulation before admission. Known inherited thrombophilia. Active malignancy. Pregnancy. Patients refusing participation. Recent major surgery or trauma within previous 4 weeks.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
One group

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Primary outcome: Incidence of venous thromboembolic events (VTE)
Time Frame: One Year

Number and proportion of adult patients with ILD who develop objectively confirmed venous thromboembolic events, defined as DVT and/or pulmonary embolism, during hospitalization.

One Year

Secondary Outcome Measures

Outcome Measure
Time Frame
Length of hospital stay
Time Frame: One year
One year
Requirement and level of respiratory support
Time Frame: One Year
One Year
ICU admission and length of ICU stay
Time Frame: One Year
One Year
In-hospital mortality
Time Frame: One Year
One Year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 1, 2026

Primary Completion (Estimated)

August 31, 2027

Study Completion (Estimated)

August 31, 2027

Study Registration Dates

First Submitted

September 5, 2026

First Submitted That Met QC Criteria

September 20, 2026

First Posted (Actual)

September 22, 2026

Study Record Updates

Last Update Posted (Actual)

September 22, 2026

Last Update Submitted That Met QC Criteria

September 20, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe